Manuel ramÃ-rez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7339926/publications.pdf

Version: 2024-02-01

141 4,091 32 57
papers citations h-index g-index

150 150 150 5828 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	Fast H3K9 methylation promoted by CXCL12 contributes to nuclear changes and invasiveness of T-acute lymphoblastic leukemia cells. Oncogene, 2022, 41, 1324-1336.	5.9	10
2	Acute lymphoblastic leukemia cells are able to infiltrate the brain subventricular zone stem cell niche and impair neurogenesis. Haematologica, 2022, , .	3.5	O
3	High BMP4 expression in low/intermediate risk BCP-ALL identifies children with poor outcome. Blood, 2022, , .	1.4	O
4	The Multi-Kinase Inhibitor EC-70124 Is a Promising Candidate for the Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia. Cancers, 2022, 14, 1593.	3.7	1
5	Mobilization with highâ€dose granulocyte colonyâ€stimulating factor alone at 12 μg/kg twice a day in highâ€risk pediatric patients: A retrospective analysis of the experience in a single center. Journal of Clinical Apheresis, 2022, 37, 420-429.	1.3	1
6	Plerixaforâ€based mobilization in pediatric healthy donors with unfavorable donor/recipient body weight ratio resulted in a better <scp>CD34</scp> ⁺ collection yield: A retrospective analysis. Journal of Clinical Apheresis, 2021, 36, 78-86.	1.3	3
7	CAR T cell therapy in B-cell acute lymphoblastic leukaemia: Insights from mathematical models. Communications in Nonlinear Science and Numerical Simulation, 2021, 94, 105570.	3.3	20
8	The Netrin-1-Neogenin-1 signaling axis controls neuroblastoma cell migration via integrin- \hat{l}^21 and focal adhesion kinase activation. Cell Adhesion and Migration, 2021, 15, 58-73.	2.7	10
9	Dual-Target CAR-Ts with On- and Off-Tumour Activity May Override Immune Suppression in Solid Cancers: A Mathematical Proof of Concept. Cancers, 2021, 13, 703.	3.7	12
10	A Mathematical Description of the Bone Marrow Dynamics during CAR T-Cell Therapy in B-Cell Childhood Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences, 2021, 22, 6371.	4.1	8
11	Integrative methylome-transcriptome analysis unravels cancer cell vulnerabilities in infant MLL-rearranged B cell acute lymphoblastic leukemia. Journal of Clinical Investigation, 2021, 131, .	8.2	14
12	Dynamical properties of feedback signalling in B lymphopoiesis: A mathematical modelling approach. Journal of Theoretical Biology, 2021, 522, 110685.	1.7	4
13	Increased Hypothalamic Anti-Inflammatory Mediators in Non-Diabetic Insulin Receptor Substrate 2-Deficient Mice. Cells, 2021, 10, 2085.	4.1	1
14	MCL-1 Inhibition Overcomes Anti-apoptotic Adaptation to Targeted Therapies in B-Cell Precursor Acute Lymphoblastic Leukemia. Frontiers in Cell and Developmental Biology, 2021, 9, 695225.	3.7	4
15	Engraftment characterization of risk-stratified AML patients in NSGS mice. Blood Advances, 2021, 5, 4842-4854.	5.2	5
16	High-Dimensional Analysis of Single-Cell Flow Cytometry Data Predicts Relapse in Childhood Acute Lymphoblastic Leukaemia. Cancers, 2021, 13, 17.	3.7	17
17	Immunotherapy with CAR-T cells in paediatric haematology-oncology. Anales De PediatrÃa (English) Tj ETQq1 1 C	0.784314 t 0.2	rgBT /Overloc
18	TYK2 Variants in B-Acute Lymphoblastic Leukaemia. Genes, 2020, 11, 1434.	2.4	4

#	Article	IF	CITATIONS
19	The choroid plexus stroma constitutes a sanctuary for paediatric B â€eell precursor acute lymphoblastic leukaemia in the central nervous system. Journal of Pathology, 2020, 252, 189-200.	4.5	10
20	sRAGE as severe acute bronchiolitis biomarker, prospective observational study. Pediatric Pulmonology, 2020, 55, 3429-3436.	2.0	1
21	Inhibition of inflammatory signaling in Pax5 mutant cells mitigates B-cell leukemogenesis. Scientific Reports, 2020, 10, 19189.	3.3	15
22	Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia. Journal of Personalized Medicine, 2020, 10, 244.	2.5	1
23	Genetic and Immune Changes Associated with Disease Progression under the Pressure of Oncolytic Therapy in A Neuroblastoma Outlier Patient. Cancers, 2020, 12, 1104.	3.7	12
24	Impaired Condensin Complex and Aurora B kinase underlie mitotic and chromosomal defects in hyperdiploid B-cell ALL. Blood, 2020, 136, 313-327.	1.4	16
25	First-in-Human, First-in-Child Trial of Autologous MSCs Carrying the Oncolytic Virus Icovir-5 in Patients with Advanced Tumors. Molecular Therapy, 2020, 28, 1033-1042.	8.2	57
26	Multiple particle tracking analysis in isolated nuclei reveals the mechanical phenotype of leukemia cells. Scientific Reports, 2020, 10, 6707.	3.3	12
27	Systemic oncolytic adenovirus delivered in mesenchymal carrier cells modulate tumor infiltrating immune cells and tumor microenvironment in mice with neuroblastoma. Oncotarget, 2020, 11, 347-361.	1.8	26
28	IL-7R is essential for leukemia-initiating cell activity of T-cell acute lymphoblastic leukemia. Blood, 2019, 134, 2171-2182.	1.4	28
29	Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia. Blood, 2019, 133, 2291-2304.	1.4	87
30	Haploidentical Stem Cell Transplantation in Children With Hematological Malignancies Using $\hat{l}\pm\hat{l}^2+$ T-Cell Receptor and CD19+ Cell Depleted Grafts: High CD56dim/CD56bright NK Cell Ratio Early Following Transplantation Is Associated With Lower Relapse Incidence and Better Outcome. Frontiers in Immunology, 2019, 10, 2504.	4.8	13
31	The Netrin-4/Laminin \hat{l}^3 1/Neogenin-1 complex mediates migration in SK-N-SH neuroblastoma cells. Cell Adhesion and Migration, 2019, 13, 33-40.	2.7	8
32	Molecular Scaffolds as Double‶argeting Agents For the Diagnosis and Treatment of Neuroblastoma. Angewandte Chemie - International Edition, 2019, 58, 3067-3072.	13.8	15
33	Molecular Scaffolds as Double‶argeting Agents For the Diagnosis and Treatment of Neuroblastoma. Angewandte Chemie, 2019, 131, 3099-3104.	2.0	4
34	CD64 on monocytes and granulocytes in severe acute bronchiolitis: Pilot study on its usefulness as a bacterial infection biomarker. Journal of Leukocyte Biology, 2018, 103, 965-971.	3.3	7
35	Circulating soluble RAGE and cell surface RAGE on peripheral blood mononuclear cells in healthy children. Journal of Pediatric Endocrinology and Metabolism, 2018, 31, 649-654.	0.9	5
36	NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL. Leukemia, 2018, 32, 633-644.	7.2	35

#	Article	IF	CITATIONS
37	Outcome of childhood leukaemia survivors and necrosis of the femoral head treated with autologous mesenchymal stem cells. Clinical and Translational Oncology, 2018, 20, 584-590.	2.4	5
38	G9a Correlates with VLA-4 Integrin and Influences the Migration of Childhood Acute Lymphoblastic Leukemia Cells. Cancers, 2018, 10, 325.	3.7	12
39	Remission of Spontaneous Canine Tumors after Systemic Cellular Viroimmunotherapy. Cancer Research, 2018, 78, 4891-4901.	0.9	33
40	Donor age matters in T-cell depleted haploidentical hematopoietic stem cell transplantation in pediatric patients: Faster immune reconstitution using younger donors. Leukemia Research, 2017, 57, 60-64.	0.8	33
41	Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia. British Journal of Cancer, 2017, 117, 256-265.	6.4	34
42	Early clinical trials in paediatric oncology in Spain: A nationwide perspective. Anales De PediatrÃa (English Edition), 2017, 87, 155-163.	0.2	0
43	Prognostic factors and outcomes for pediatric patients receiving an haploidentical relative allogeneic transplant using CD3/CD19-depleted grafts. Bone Marrow Transplantation, 2016, 51, 1211-1216.	2.4	29
44	Muscling In on Cancer. New England Journal of Medicine, 2016, 375, 892-894.	27.0	44
45	Influence of carrier cells on the clinical outcome of children with neuroblastoma treated with high dose of oncolytic adenovirus delivered in mesenchymal stem cells. Cancer Letters, 2016, 371, 161-170.	7.2	61
46	Physical function and quality of life in patients with chronic GvHD: a summary of preclinical and clinical studies and a call for exercise intervention trials in patients. Bone Marrow Transplantation, 2016, 51, 13-26.	2.4	60
47	Immunomagnetic T Cell Depletion: an Analysis of Variables Affecting Final Cell Yield. Clinical Laboratory, 2016, 62, 1243-1248.	0.5	1
48	The NFKB Inducing Kinase Modulates Hematopoiesis During Stress. Stem Cells, 2015, 33, 2825-2837.	3.2	28
49	Patient-derived mesenchymal stem cells as delivery vehicles for oncolytic virotherapy: novel state-of-the-art technology. Oncolytic Virotherapy, 2015, 4, 149.	6.0	30
50	Chemokines and relapses in childhood acute lymphoblastic leukemia: A role in migration and in resistance to antileukemic drugs. Blood Cells, Molecules, and Diseases, 2015, 55, 220-227.	1.4	39
51	Serum sRAGE as a Potential Biomarker for Pediatric Bronchiolitis: A Pilot Study. Lung, 2015, 193, 19-23.	3.3	18
52	A new targeting agent for the selective drug delivery of nanocarriers for treating neuroblastoma. Journal of Materials Chemistry B, 2015, 3, 4831-4842.	5.8	43
53	Mesenchymal stem cells derived from low risk acute lymphoblastic leukemia patients promote NK cell antitumor activity. Cancer Letters, 2015, 363, 156-165.	7.2	15
54	Effects of local administration of allogenic adipose tissue-derived mesenchymal stem cells on functional recovery in experimental traumatic brain injury. Brain Injury, 2015, 29, 1497-1510.	1.2	24

#	Article	IF	CITATIONS
55	A phase I/II trial of interleukin-15–stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors. Cytotherapy, 2015, 17, 1594-1603.	0.7	69
56	Understanding graft-versus-host disease. Preliminary findings regarding the effects of exercise in affected patients. Exercise Immunology Review, 2015, 21, 80-112.	0.4	14
57	Optimal Effector Functions in Human Natural Killer Cells Rely upon Autocrine Bone Morphogenetic Protein Signaling. Cancer Research, 2014, 74, 5019-5031.	0.9	22
58	Exercise training can induce cardiac autophagy at end-stage chronic conditions: Insights from a graft-versus-host-disease mouse model. Brain, Behavior, and Immunity, 2014, 39, 56-60.	4.1	29
59	Hybrid Enzymeâ€Polymeric Capsules/Mesoporous Silica Nanodevice for In Situ Cytotoxic Agent Generation. Advanced Functional Materials, 2014, 24, 4625-4633.	14.9	48
60	PEG-pHPMAm-based polymeric micelles loaded with doxorubicin-prodrugs in combination antitumor therapy with oncolytic vaccinia viruses. Polymer Chemistry, 2014, 5, 1674-1681.	3.9	17
61	Dopamine Mobilizes Mesenchymal Progenitor Cells Through D2-Class Receptors and Their PI3K/AKT Pathway. Stem Cells, 2014, 32, 2529-2538.	3.2	8
62	Superselective Intracerebral Catheterization for Administration of Oncolytic Virotherapy in a Case of Diffuse Intrinsic Pontine Glioma. Journal of Pediatric Hematology/Oncology, 2014, 36, e430-e432.	0.6	8
63	Mesenchymal Stromal Cells Derived from the Bone Marrow of Acute Lymphoblastic Leukemia Patients Show Altered BMP4 Production: Correlations with the Course of Disease. PLoS ONE, 2014, 9, e84496.	2.5	39
64	A Role for the CXCR3/CXCL10 Axis in Rasmussen Encephalitis. Pediatric Neurology, 2013, 49, 451-457.e1.	2.1	28
65	Detection of occult cerebrospinal fluid involvement during maintenance therapy identifies a group of children with acute lymphoblastic leukemia at high risk for relapse. American Journal of Hematology, 2013, 88, 359-364.	4.1	54
66	Defining "poor mobilizer―in pediatric patients who need an autologous peripheral blood progenitor cell transplantation. Cytotherapy, 2013, 15, 132-137.	0.7	14
67	Exercise Benefits in Chronic Graft versus Host Disease. Medicine and Science in Sports and Exercise, 2013, 45, 1703-1711.	0.4	23
68	Effects of Exercise Interventions in Graft-Versus-Host Disease Models. Cell Transplantation, 2013, 22, 2409-2420.	2.5	11
69	Clinical Proteomics in Cancer Research. Current Proteomics, 2013, 10, 179-191.	0.3	1
70	Early evaluation of immune reconstitution following allogeneic CD3/CD19-depleted grafts from alternative donors in childhood acute leukemia. Bone Marrow Transplantation, 2012, 47, 1419-1427.	2.4	37
71	Enrichment of neural-related genes in human mesenchymal stem cells from neuroblastoma patients. International Journal of Molecular Medicine, 2012, 30, 365-373.	4.0	3
72	Spontaneous Resolution of Hypereosinophilic Syndrome in an Infant Without Treatment. Journal of Pediatric Hematology/Oncology, 2012, 34, 450-452.	0.6	0

#	Article	IF	Citations
73	CitometrÃa de flujo: qué puede aportar al diagnóstico hematológico en pediatrÃa. Anales De Pediatria Continuada, 2012, 10, 282-285.	0.1	О
74	Immune-Mediated Mechanisms in the Pathogenesis of Hopkins Syndrome. Pediatric Neurology, 2012, 47, 373-374.	2.1	6
75	Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4+ and MLL-germline acute lymphoblastic leukemia. Leukemia, 2012, 26, 2360-2366.	7.2	55
76	Mesenchymal Stem Cells for the Treatment of Cancer. , 2012, , 177-183.		0
77	Blood Dendritic Cells Suppress NK Cell Function and Increase the Risk of Leukemia Relapse after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 598-607.	2.0	23
78	Allogeneic hematopoietic transplantation using haploidentical donor vs. unrelated cord blood donor in pediatric patients: a single-center retrospective study. European Journal of Haematology, 2011, 87, 46-53.	2.2	29
79	Exercise Training and Cytokines in Breast Cancer Survivors. International Journal of Sports Medicine, 2011, 32, 461-467.	1.7	63
80	Preliminary Findings of a 4-Month Intrahospital Exercise Training Intervention on IGFs and IGFBPs in Children with Leukemia. Journal of Strength and Conditioning Research, 2010, 24, 1292-1297.	2.1	28
81	Graft Manipulation and Reduced-intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation From Mismatched Unrelated and Mismatched/Haploidentical Related Donors in Pediatric Leukemia Patients. Journal of Pediatric Hematology/Oncology, 2010, 32, e85-e90.	0.6	34
82	Analysis of Clinical Outcome and Survival in Pediatric Patients Undergoing Extracorporeal Photopheresis for the Treatment of Steroid-refractory GVHD. Journal of Pediatric Hematology/Oncology, 2010, 32, 589-593.	0.6	24
83	Nuclear factor-Â B inducing kinase is required for graft-versus-host disease. Haematologica, 2010, 95, 2111-2118.	3.5	7
84	Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study. Cancer Gene Therapy, 2010, 17, 476-483.	4.6	126
85	Exercise during Hematopoietic Stem Cell Transplant Hospitalization in Children. Medicine and Science in Sports and Exercise, 2010, 42, 1045-1053.	0.4	93
86	Mesenchymal stem cells: biological properties and clinical applications. Expert Opinion on Biological Therapy, 2010, 10, 1453-1468.	3.1	147
87	Oncolytic virotherapy for neuroblastoma. Discovery Medicine, 2010, 10, 387-93.	0.5	10
88	Mobilisation of mesenchymal cells in cardiac patients: is intense exercise necessary?. British Journal of Sports Medicine, 2009, 43, 221-223.	6.7	8
89	ALLOGENEIC CORD BLOOD TRANSPLANTATION IN CHILDREN WITH HEMATOLOGICAL MALIGNANCIES: A Long-Term Follow-Up Single-Center Study. Pediatric Hematology and Oncology, 2009, 26, 165-174.	0.8	12
90	KIR–HLA receptorâ€ligand mismatch associated with a graftâ€versusâ€tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors. Pediatric Blood and Cancer, 2009, 53, 120-124.	1.5	64

#	Article	IF	Citations
91	Peripheral blood progenitor cell collection adverse events for childhood allogeneic donors: variables related to the collection and safety profile. British Journal of Haematology, 2009, 144, 909-916.	2.5	31
92	A Role For NF-KB Inducing Kinase (NIK) In Graft Versus Host Reactions. Biology of Blood and Marrow Transplantation, 2009, 15 , 118 .	2.0	0
93	Chemokines in Leukemic Infiltration of the Central Nervous System in Childhood Acute Lymphoblastic Leukemia Blood, 2009, 114, 1627-1627.	1.4	2
94	Intentional induction of mixed haematopoietic chimerism as platform for cellular therapy after HLAâ€matched allogeneic stem cell transplantation in childhood leukaemia patients. British Journal of Haematology, 2008, 140, 340-343.	2.5	10
95	Benefits of Intrahospital Exercise Training after Pediatric Bone Marrow Transplantation. International Journal of Sports Medicine, 2008, 29, 439-446.	1.7	99
96	Functional Capacity of Children with Leukemia. International Journal of Sports Medicine, 2008, 29, 163-167.	1.7	76
97	Extracorporeal photochemotherapy for steroid-refractory graft-versus-host disease in low-weight pediatric patients. Immunomodulatory effects and clinical outcome. Haematologica, 2008, 93, 1278-1280.	3.5	26
98	Effects of an Intrahospital Exercise Program Intervention for Children with Leukemia. Medicine and Science in Sports and Exercise, 2007, 39, 13-21.	0.4	153
99	EARLY-PHASE ADAPTATIONS TO INTRAHOSPITAL TRAINING IN STRENGTH AND FUNCTIONAL MOBILITY OF CHILDREN WITH LEUKEMIA. Journal of Strength and Conditioning Research, 2007, 21, 173-177.	2.1	64
100	Mesenchymal Stem Cells are of Recipient Origin in Pediatric Transplantations Using Umbilical Cord Blood, Peripheral Blood, or Bone Marrow. Journal of Pediatric Hematology/Oncology, 2007, 29, 388-392.	0.6	17
101	162: Fludarabine-based reduced-intensity conditioning for allogeneic transplantation in children with malignant and non-malignant diseases. Biology of Blood and Marrow Transplantation, 2007, 13, 61.	2.0	2
102	PBSC collection in extremely low weight infants: a single-center experience. Cytotherapy, 2007, 9, 356-361.	0.7	11
103	Changes in L-Selectin Expression by T Lymphocytes after Extracorporeal Photochemotherapy Blood, 2007, 110, 1961-1961.	1.4	0
104	Intentional induction of immune-hematopoietic mixed chimerism as a platform for early cellular therapy in pediatric leukemia patients after allogeneic transplantation: Enhancing GvL effect while avoiding GvHD. Biology of Blood and Marrow Transplantation, 2006, 12, 53-54.	2.0	1
105	Adipose Tissueâ€Derived Mesenchymal Stem Cells Have In Vivo Immunosuppressive Properties Applicable for the Control of the Graftâ€Versusâ€Host Disease. Stem Cells, 2006, 24, 2582-2591.	3.2	649
106	Mobilisation of mesenchymal cells into blood in response to skeletal muscle injury. British Journal of Sports Medicine, 2006, 40, 719-722.	6.7	53
107	Physical activity during treatment in children with leukemia: a pilot study. Applied Physiology, Nutrition and Metabolism, 2006, 31, 407-413.	1.9	67
108	Engraftment kinetics of human CD34+ cells from cord blood and mobilized peripheral blood co-transplanted into NOD/SCID mice. Bone Marrow Transplantation, 2005, 35, 271-275.	2.4	8

#	Article	IF	Citations
109	Tumor cells as cellular vehicles to deliver gene therapies to metastatic tumors. Cancer Gene Therapy, 2005, 12, 341-349.	4.6	46
110	Full donor chimerism by day 30 after allogeneic peripheral blood progenitor cell transplantation is associated with a low risk of relapse in pediatric patients with hematological malignancies. Leukemia, 2005, 19, 504-506.	7.2	24
111	Intrahospital supervised exercise training: a complementary tool in the therapeutic armamentarium against childhood leukemia. Leukemia, 2005, 19, 1334-1337.	7.2	26
112	In Vitro and In Vivo Immunomodulatory Effects of Mesenchymal Stem Cells from Adipose Tissue Blood, 2005, 106, 3098-3098.	1.4	3
113	Engraftment syndrome after autologous peripheral blood progenitor cell transplantation in pediatric patients: a prospective evaluation of risk factors and outcome. Bone Marrow Transplantation, 2004, 34, 1051-1055.	2.4	20
114	A prospective randomized study of clinical and economic consequences of using G-CSF following autologous peripheral blood progenitor cell (PBPC) transplantation in children. Bone Marrow Transplantation, 2004, 34, 1077-1081.	2.4	14
115	Transplantation of marrow cells from children with standard risk-acute lymphoblastic leukemia at the end of therapy into NOD/SCID mice for detecting residual leukemic cells with in vivo growth potential. Leukemia Research, 2003, 27, 1153-1157.	0.8	3
116	Loss of heterozygosity of p16 correlates with minimal residual disease at the end of the induction therapy in non-high risk childhood B-cell precursor acute lymphoblastic leukemia. Leukemia Research, 2002, 26, 817-820.	0.8	10
117	Efficient and nontoxic adenoviral purging method for autologous transplantation in breast cancer patients. Cancer Research, 2002, 62, 5013-8.	0.9	12
118	Ex vivo expansion of umbilical cord blood (UCB) CD34+ cells alters the expression and function of $\hat{l}\pm4\hat{l}^21$ and $\hat{l}\pm5\hat{l}^21$ integrins. British Journal of Haematology, 2001, 115, 213-221.	2.5	28
119	Human CD34+ cell preparations contain over 100-fold greater NOD/SCID mouse engrafting capacity than do CD34â^ cell preparations. Experimental Hematology, 2001, 29, 910-921.	0.4	49
120	Clinical and economic comparison of allogeneic peripheral blood progenitor cell and bone marrow transplantation for acute lymphoblastic leukemia in children. Bone Marrow Transplantation, 2000, 26, 269-273.	2.4	16
121	Ex VivoCulture of Cord Blood CD34+Cells Expands Progenitor Cell Numbers, Preserves Engraftment Capacity in Nonobese Diabetic/Severe Combined Immunodeficient Mice, and Enhances Retroviral Transduction Efficiency. Human Gene Therapy, 1999, 10, 2927-2940.	2.7	38
122	Human Hematopoietic Stem/Progenitor Cells Generate CD5 ⁺ B Lymphoid Cells in NOD/SCID Mice. Stem Cells, 1999, 17, 242-252.	3.2	16
123	G-CSF-mobilized PBSCT in children with AML in first complete remission. Bone Marrow Transplantation, 1999, 23, 975-976.	2.4	1
124	Quantity and quality of engrafting cells in cord blood and autologous mobilized peripheral blood. Biology of Blood and Marrow Transplantation, 1999, 5, 69-76.	2.0	34
125	COMPARISONS OF ALLOREACTIVE POTENTIAL OF CLINICAL HEMATOPOIETIC GRAFTS1. Transplantation, 1999, 68, 628-635.	1.0	15
126	Delayed engraftment of nonobese diabetic/severe combined immunodeficient mice transplanted with ex vivo-expanded human CD34(+) cord blood cells. Blood, 1999, 93, 1097-105.	1.4	31

#	Article	IF	CITATIONS
127	Megatherapy in children with high-risk Ewing's sarcoma in first complete remission. Bone Marrow Transplantation, 1998, 21, 795-799.	2.4	29
128	Biology of CD34+CD38-Cells in Lymphohematopoiesis. Leukemia and Lymphoma, 1998, 31, 285-293.	1.3	34
129	CBFÎ ² -SMMHC, Expressed in M4eo Acute Myeloid Leukemia, Reduces p53 Induction and Slows Apoptosis in Hematopoietic Cells Exposed to DNA-Damaging Agents. Blood, 1998, 92, 4344-4352.	1.4	6
130	Flt3high and Flt3low CD34+ progenitor cells isolated from human bone marrow are functionally distinct. Blood, 1998, 91, 1947-58.	1.4	25
131	Mature human hematopoietic cells in donor bone marrow complicate interpretation of stem/progenitor cell assays in xenogeneic hematopoietic chimeras. Experimental Hematology, 1998, 26, 332-44.	0.4	37
132	In vivo engraftment potential of clinical hematopoietic grafts. Journal of Investigative Medicine, 1998, 46, 303-11.	1.6	17
133	CBFbeta-SMMHC, expressed in M4eo acute myeloid leukemia, reduces p53 induction and slows apoptosis in hematopoietic cells exposed to DNA-damaging agents. Blood, 1998, 92, 4344-52.	1.4	14
134	Cord Blood Transplantation: A Promising Future. Pediatrics, 1997, 99, 475-475.	2.1	4
135	Clinical relevance of T-cell receptor delta gene rearrangements in childhood B-precursor cell acute lymphoblastic leukaemia. British Journal of Haematology, 1997, 99, 308-313.	2.5	5
136	Tnk1: a novel intracellular tyrosine kinase gene isolated from human umbilical cord blood CD34+/Lin-/CD38- stem/progenitor cells. Oncogene, 1996, 12, 903-13.	5.9	49
137	Pediatric experience with autologous peripheral blood progenitor cell transplantation: influence of CD34+ cell dose in engraftment kinetics. Bone Marrow Transplantation, 1996, 18, 699-703.	2.4	24
138	Chimerism after allogeneic hematopoietic cell transplantation in childhood acute lymphoblastic leukemia. Bone Marrow Transplantation, 1996, 18, 1161-5.	2.4	24
139	Complicated Pulmonary Aspergillosis with Pneumothorax and Pneumopericardium in a Child with Acute Lymphoblastic Leukemia. Pediatric Hematology and Oncology, 1995, 12, 195-199.	0.8	14
140	G-CSF after autologous bone marrow transplantation for malignant diseases in children. Spanish Working Party for Bone Marrow Transplantation in Children. Bone Marrow Transplantation, 1995, 15, 349-51.	2.4	14
141	T-Cell Depleted Haploidentical Transplantation in Children With Hematological Malignancies: A Comparison Between CD3+/CD19+ and TCRαβ+/CD19+ Depletion Platforms. Frontiers in Oncology, 0, 12, .	2.8	1